BlackRock Inc. Invests $400.55 Million in Ingevity Corporation $NGVT

Key Points

• BlackRock acquired 5.36 million Ingevity shares worth approximately $400.5 million, making it the company’s largest disclosed institutional holder with a 15.6% stake. Institutional investors collectively own 91.59% of NGVT.
• Ingevity reported quarterly EPS of $1.74, exceeding estimates of $1.33, while revenue reached $314.1 million. The company maintained fiscal 2026 EPS guidance of $5.00–$5.45.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average $80 price target; meanwhile, insiders sold 18,297 shares worth about $1.38 million over the past 90 days.

BlackRock Inc. purchased a new stake in shares of Ingevity Corporation (NYSE:NGVT - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,364,204 shares of the company's stock, valued at approximately $400,545,000. BlackRock Inc. owned 15.60% of Ingevity as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new stake in Ingevity in the fourth quarter worth about $27,000. Meeder Asset Management Inc. acquired a new position in Ingevity during the 4th quarter valued at about $33,000. Geneos Wealth Management Inc. lifted its position in Ingevity by 85.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company's stock valued at $36,000 after purchasing an additional 387 shares during the period. Headlands Technologies LLC bought a new position in shares of Ingevity in the 2nd quarter valued at about $46,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Ingevity in the 4th quarter valued at about $47,000. Institutional investors own 91.59% of the company's stock.

Insider Activity at Ingevity

In related news, SVP Terrance M. Dyer sold 496 shares of Ingevity stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $68.49, for a total transaction of $33,971.04. Following the transaction, the senior vice president owned 7,202 shares of the company's stock, valued at $493,264.98. This trade represents a 6.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Ryan C. Fisher sold 2,709 shares of Ingevity stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $73.72, for a total transaction of $199,707.48. Following the transaction, the senior vice president directly owned 15,722 shares in the company, valued at $1,159,025.84. The trade was a 14.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,297 shares of company stock worth $1,381,452 in the last ninety days. Company insiders own 0.88% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on NGVT. Wall Street Zen downgraded shares of Ingevity from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 1st. Weiss Ratings raised shares of Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $80.00.

Ingevity Trading Up 0.4%

NYSE NGVT opened at $69.08 on Wednesday. Ingevity Corporation has a 12 month low of $45.85 and a 12 month high of $79.29. The stock has a 50-day simple moving average of $73.72 and a 200 day simple moving average of $71.84. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52. The company has a market capitalization of $2.38 billion, a PE ratio of 46.99 and a beta of 1.16.

Ingevity (NYSE:NGVT - Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.33 by $0.41. The firm had revenue of $314.10 million for the quarter, compared to analysts' expectations of $312.20 million. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Research analysts forecast that Ingevity Corporation will post 5.4 EPS for the current year.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

Want to see what other hedge funds are holding NGVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ingevity Corporation (NYSE:NGVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.